European Auto Stocks Rise as EU-China Trade Deal Targets Hybrid Imports 
Meta Launches Muse Wonder AI Models, Shares Rise 3.7% 
Deutsche Bank CEO Urges Faster German Economic Reforms 
Bumble Shares Surge 50% on $1 Billion Buyout Talks 
TSMC Profit Set to Surge 65% as AI Chip Demand Drives Record Earnings 
Bank of America Predicts Yen Rebound as USD/JPY Faces Risks 
Samsung, SK Hynix Shares Plunge as China Chip Competition Grows 
US Dollar Near 18-Month High Ahead of Inflation Data 
FAA Warns US Airlines Over Saudi Arabia Flight Risks 
South Korea Blocks 27 Crypto Exchange Websites in Regulatory Crackdown 
Global Stocks Mixed as Oil Falls Ahead of US Earnings 
Albertsons Seeks $9.3 Billion From Kroger Over Failed Merger 
Nvidia’s China AI Chip Market Share Falls to 34% as Huawei Gains Ground 
S&P 500 Rally Masks Losses for Over 40% of Stocks in 2026 
Fed's Hammack Urges Faster Rate Hikes to Fight Inflation 
Asian Currencies Steady as Dollar Nears 18-Month High Ahead of US CPI 
US Stock Futures Rise as Oil Prices Fall Ahead of Q3 Earnings 
Add as a preferred source on Google
Samsung Biologics just opened the largest Contract Development and Manufacturing Organization (CDMO) plant in the world, and it is located in Incheon, South Korea. The biotech firm is now hoping that through its new pharmaceutical facility, it will be able to replicate the success of its chip manufacturing business.
Samsung Biologics inaugurated the plant on Tuesday, Oct. 11, and it was attended by the vice chairman of Samsung Electronics, Lee Jae Yong. The facility is now the biopharma firm’s fourth factory.
The company usually has an annual production capacity of 240,000 liters and this will now become 420,000 liters as the new plant starts its partial operation. The construction of the Songdo plant began in 2020, and it is expected to go into full operation next year.
As per Korea Joongang Daily, once it runs in full force, Samsung Biologics is expecting to further increase its production capacity up to 620,000 liters. The company said this amount is equivalent to almost 30% of the global contract manufacturing capacity for biopharma firms.
With this volume, Samsung Biologics defeated Switzerland’s Lonza Group AG and Germany's Boehringer Ingelheim pharmaceutical and biotech companies.
In any case, Samsung invested KRW2 trillion or about $1.4 billion for the construction of its new Songdo plant, and in the future, the company may spend a total of KRW7 trillion on building its fifth, sixth, seventh, and eighth plants in the same region but on another site. Samsung Biologics is expanding its facilities to accommodate more orders from its major global clients, such as Pfizer, GlaxoSmithKline, Moderna, Eli Lilly, and AstraZeneca.
Meanwhile, the Samsung chief met with the senior executives of Samsung Biologics and Samsung Bioepis after the inauguration ceremony for the Songdo factory. They talked about mid and long-term strategies to improve competitiveness as CDMO and a biosimilar manufacturer.
The Korea Times reported that at the meeting, Lee Jae Yong vowed to put in a new investment of KRW7.5 trillion or $5.2 billion to widen the gap from its rivals in the bio business and move ahead to become the leader in the industry. He said that Samsung will release the fund for its biotech unit by 2032.
